Dario Altieri

Source: Wikipedia, the free encyclopedia.
Dario Carlo Altieri
OccupationResearcher

Dario Carlo Altieri, an Italian-born physician-scientist, is the president and CEO of

The Wistar Institute
.

Biography

Altieri was born in

University of Massachusetts Medical School.[1][4]

Research

His research has focused on

Inhibitors of Apoptosis (IAP), a family of genes essential for proliferation and survival of cells. His work has identified survivin, one of these IAP genes, is over-produced in almost every human cancer, and his team is currently studying the biology of survivin and how it could be used to develop treatments for cancer.[5][6][7]

Altieri has also been involved in the development of

mitochondria
in cancerous cells.

In 2013, Altieri and his team received a $1.5 million grant from the United States Department of Defense to prepare the drug for human trials.[8][9] He also co-founded the Cancer Biology Training Consortium and the Pancreatic Cancer alliance in 2005.[10]

Further reading

  • "Dario C. Altieri Inventions, Patents and Patent Applications". Justia Patents Search. 2021-12-23. Retrieved 2023-03-15.<
  • "A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer - Full Text View". ClinicalTrials.gov. 2021-04-01. Retrieved 2023-03-15.

References

  1. ^
    The University of Pennsylvania
    . Retrieved 2 March 2015.
  2. ^ "Cancer Biologist Dario Altieri to Lead the Wistar Institute Cancer Center". The Wistar Institute. Retrieved 11 February 2014.
  3. ^ a b "Biography Dario C. Altieri, MD.; Association of American Cancer Institutes".
  4. ^ "Gene "survivin" inhibits cell death" (PDF). Yale Cancer Center. Retrieved 2023-03-15.
  5. The Wistar Institute
    . Retrieved 28 January 2014.
  6. The Journal of Clinical Investigation
    . Retrieved 28 January 2014.
  7. ^ "Emerging Research Fronts - 2009". ScienceWatch. Retrieved 11 February 2014.
  8. The Wistar Institute. Archived from the original
    on 22 February 2014. Retrieved 28 January 2014.
  9. ^ "Combinatorial Drugs Target Cancer Cell Mitochonndria". biotechdaily.com. Retrieved 11 February 2014.
  10. The Wistar Institute
    . Retrieved 28 January 2014.

External links